Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008

Ovarian Neoplasms

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 18 articles: HTML format

Single Articles

May 2008
1. CAMCI C , Sevinc A, Aslan Y, Kalender ME, et al
   Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
2. CHEN J , Adikari M, Pallai R, Parekh HK, et al
   Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
   Cancer Chemother Pharmacol. 2008;61:979-87.
   PubMed     Related articles    Abstract available
   
   
   January 2008
3. JI C , Cao C, Lu S, Kivlin R, et al
   Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
4. BANERJI U , Sain N, Sharp SY, Valenti M, et al
   An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   October 2007
5. KOENSGEN D , Stengel D, Belau A, Klare P, et al
   Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
   Cancer Chemother Pharmacol. 2007;.
   PubMed     Related articles    Abstract available
   
   
   September 2007
6. SMITH JA , Gaikwad A, Yu J, Wolf JK, et al
   In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines.
   Cancer Chemother Pharmacol. 2007;.
   PubMed     Related articles    Abstract available
   
   
   May 2007
7. ROYER B , Delroeux D, Guardiola E, Combe M, et al
   Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
   Cancer Chemother Pharmacol. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
8. VARMA R , Hector S, Greco WR, Clark K, et al
   Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
   Cancer Chemother Pharmacol. 2007;59:711-23.
   PubMed     Related articles    Abstract available
   
   
   April 2007
9. FERRANDINA G , Legge F, Mey V, Nannizzi S, et al
   A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.
   Cancer Chemother Pharmacol. 2007;.
   PubMed     Related articles    Abstract available
   
   
   March 2007
10. SEHOULI J , Stengel D, Mustea A, Camara O, et al
    Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
11. VASSILEVA V , Grant J, De Souza R, Allen C, et al
    Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    February 2007
12. SAMIMI G , Kishimoto S, Manorek G, Breaux JK, et al
    Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Cancer Chemother Pharmacol. 2007;59:301-12.
    PubMed     Related articles    Abstract available
    
    
    January 2007
13. DIAS ML , Carvalho JP, Rodrigues DG, Graziani SR, et al
    Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Cancer Chemother Pharmacol. 2007;59:105-11.
    PubMed     Related articles    Abstract available
    
    
    November 2006
14. STATHOPOULOS GP , Malamos NA, Aravantinos G, Rigatos S, et al
    Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    September 2006
15. CHENG TC , Manorek G, Samimi G, Lin X, et al
    Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
    Cancer Chemother Pharmacol. 2006;58:384-95.
    PubMed     Related articles    Abstract available
    
    
    July 2006
16. DEVALAPALLY H , Shenoy D, Little S, Langer R, et al
    Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
17. ROSE WC , Marathe PH, Jang GR, Monticello TM, et al
    Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
    Cancer Chemother Pharmacol. 2006;58:73-85.
    PubMed     Related articles    Abstract available
    
    
    May 2006
18. LU H , Li B, Kang Y, Jiang W, et al
    Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: